Skin News and Research

RSS

Women and children important during groundwater arsenic pollution fieldwork, says geologist

A Kansas State University geologist and graduate student are finding that the most important tools in their fieldwork on groundwater arsenic pollution are women and children armed with pamphlets and testing kits.

24 Oct 2009

Human clinical trials of TissuGlu to commence in Germany

Cohera Medical, Inc. announced today that it has received approval to begin human clinical trials of its lead product TissuGlu® in Germany. Receipt of the approval allows Cohera Medical to proceed with patient recruitment and initiation of an investigational study of the company's novel internal surgical adhesive being developed for its first intended use to adhere surgical tissues together in large flap surgeries.

24 Oct 2009

Keraderm raises $2.5 million from institutional investor

Keraderm Corp. announced the closing today of a $2.5 million dollar Series A investment by NewVa Capital Partners, LP. Currently starting clinical trials, the company's platform harnesses phototherapy technology to treat nail and skin infections. NewVa Capital Partners is a private equity and venture capital fund managed by Third Security, LLC and provides early stage investments in companies located or considering location in the NewVa region of southwest Virginia. This is Keraderm's first institutional investment round.

24 Oct 2009

Safe and gentle personal care products from XanGo

According to a March 2009 study by the Environmental Protection Agency, 61 percent of the children's bath products tested were found to contain formaldehyde and 1,4-dioxane, both of which are probable carcinogens.

24 Oct 2009

avVaa World Health Care Products to launch third Direct TV Media Test

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced their third Direct TV Media Test is scheduled to launch on Thursday October 29.

24 Oct 2009

Sickle cell disease can be treated with resveratrol extract, according to researchers

An extract in red grape skin may be a new treatment for sickle cell disease, Medical College of Georgia researchers say.

23 Oct 2009

Modified NAGA: New enzyme for enzyme replacement therapy

A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease.

23 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Study finds link between high levels of pesticide exposure and suicidal thoughts

A new study in China has found that people with higher levels of pesticide exposure are more likely to have suicidal thoughts. The study was carried out by Dr Robert Stewart from the Institute of Psychiatry at King's College London together with scientists from Tongde Hospital Zhejiang Province.

23 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America, 47th Annual Meeting, in Philadelphia on Oct. 29 to Nov. 1, 2009.

23 Oct 2009

Theravance earns milestone payment for bactericidal, injectable lipoglycopeptide antibiotic

Theravance, Inc. announced today that it has earned a milestone payment of $20 million for the U.S. Food and Drug Administration (FDA) approval of VIBATIV (telavancin) and supplying its collaboration partner, Astellas Pharma US, Inc. (Astellas), with the launch inventory for the first commercial sale in the United States.

23 Oct 2009

Majority of allergy patients can be vaccinated against swine flu after evaluation by an allergist

Once supply catches up with the immediate demand for H1N1 "swine" flu vaccine, some allergy patients who could benefit from the vaccine may needlessly avoid it due to confusion over who should, and should not, be vaccinated, cautions Dr. Peter R. Smith, a board-certified allergist and clinical immunologist with Allergy Partners of Fredericksburg, Virginia.

23 Oct 2009

NNu Skin Enterprises signs research agreements to develop next-generation skin care and nutritional products

Nu Skin Enterprises, Inc. today announced that it has entered into research agreements with Stanford University and LifeGen Technologies, a genomics company based in Madison, Wis. LifeGen co-founders, Richard Weindruch, Ph.D., and Tomas Prolla, Ph.D., will also hold positions on the newly formed Nu Skin Anti-aging Scientific Advisory Board.

23 Oct 2009

Smith & Nephew to present comprehensive portfolio of advanced wound management products at Annual Clinical Symposium

The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew Plc (LSE: SN; NYSE: SNN), announced today that clinicians will present a total of 20 clinical posters featuring its Negative Pressure Wound Therapy (NPWT) Systems and ALLEVYN(TM) AG, ALLEVYN AG Gentle, ACTICOAT(TM) and IODOSORB(TM) advanced wound dressings during the 24th Annual Clinical Symposium on Advances in Skin and Wound Care's poster session. The poster session opens at 10:30am CT on October 23, 2009.

22 Oct 2009

Ansell Healthcare to demonstrate its latest barrier protective innovations at the Arab Health 2010

Ansell Healthcare, a global leader in barrier protective solutions, is the developer of the Gammex(R) medical gloves, a series acclaimed by surgeons worldwide for its exceptional combination of high protection and comfort levels.

22 Oct 2009

Cosmetic procedures for a competitive edge in the workplace

As the unemployment numbers heat up, so does the competition for available jobs. To get an edge, increasing numbers of job seekers are looking to cosmetic procedures to give them confidence and a competitive edge in the workplace. Indeed, a recent survey released by The American Society of Plastic Surgeons (ASPS) supports this.

22 Oct 2009

SAEC to collaborate with HMORN to improve the safe use of drugs

The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with the HMO Research Network (HMORN) to improve the safe use of drugs by exploring why the genetic makeup of some individuals makes them more likely to experience serious drug-related adverse events (SAEs).

22 Oct 2009

Grand Challenges Explorations grant for Seventh Sense Biosystems

Seventh Sense Biosystems announced today that it has received a Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Dr. Howard Bernstein, titled “On-skin and Intra-dermal Malaria Diagnostics with Unprecedented Simplicity of Use Based on Bio-Responsive Particles and Interstitial Fluid Analysis.”

22 Oct 2009

Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions

Dermatologists agree that topical fixed-combination products containing clindamycin (clin) and benzoyl peroxide (BPO) are effective in the treatment of acne. However, products containing BPO concentrations at 5% or higher may limit use due to associated dryness and irritation in some patients.

22 Oct 2009

Skin News and Research

Women and children important during groundwater arsenic pollution fieldwork, says geologist

Human clinical trials of TissuGlu to commence in Germany

Keraderm raises $2.5 million from institutional investor

Safe and gentle personal care products from XanGo

avVaa World Health Care Products to launch third Direct TV Media Test

Sickle cell disease can be treated with resveratrol extract, according to researchers

Modified NAGA: New enzyme for enzyme replacement therapy

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Study finds link between high levels of pesticide exposure and suicidal thoughts

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Theravance earns milestone payment for bactericidal, injectable lipoglycopeptide antibiotic

Majority of allergy patients can be vaccinated against swine flu after evaluation by an allergist

NNu Skin Enterprises signs research agreements to develop next-generation skin care and nutritional products

Smith & Nephew to present comprehensive portfolio of advanced wound management products at Annual Clinical Symposium

Ansell Healthcare to demonstrate its latest barrier protective innovations at the Arab Health 2010

Cosmetic procedures for a competitive edge in the workplace

SAEC to collaborate with HMORN to improve the safe use of drugs

Grand Challenges Explorations grant for Seventh Sense Biosystems

Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News